Drug Profile


Alternative Names: Anti-HIV gene therapy - VIRxSYS; VRX 496; VRX496

Latest Information Update: 01 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VIRxSYS Corporation
  • Developer University of Pennsylvania; VIRxSYS Corporation
  • Class Antivirals; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action HIV replication inhibitors; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 01 Sep 2015 Phase-II development for HIV infections is ongoing in USA
  • 22 Jul 2010 Lexgenleucel-T is still in phase II trials for HIV infections in USA
  • 22 May 2010 Adverse events data from a phase II trial in HIV infections released by VIRxSYS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top